Nautilus Biotechnology, Inc. (NAUT)

US — Healthcare Sector
Peers: NRIX  SEER  QSI  HCWB  MNOV  CRBU  HUMA 

Automate Your Wheel Strategy on NAUT

With Tiblio's Option Bot, you can configure your own wheel strategy including NAUT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NAUT
  • Rev/Share 0.0
  • Book/Share 1.4353
  • PB 0.5231
  • Debt/Equity 0.1556
  • CurrentRatio 18.5234
  • ROIC -0.1867

 

  • MktCap 94829794.0
  • FreeCF/Share -0.4461
  • PFCF -1.6848
  • PE -1.4422
  • Debt/Assets 0.1322
  • DivYield 0
  • ROE -0.3253

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade NAUT Goldman Neutral Sell -- $1.75 Dec. 5, 2024

News

About Nautilus Biotechnology, Inc. (NAUT)

  • IPO Date 2020-08-07
  • Website https://www.nautilus.bio
  • Industry Biotechnology
  • CEO Sujal M. Patel
  • Employees 134
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.